Current disease status-Recurrent leukemia - Page 3 of 8 Posts on Medivizor
Navigation Menu

Current disease status-Recurrent leukemia Posts on Medivizor

Is entospletinib an effective treatment for relapsed or unresponsive chronic lymphocytic leukemia?

Posted by on Mar 12, 2019 in Leukemia | 0 comments

In a nutshell This study examined if entospletinib can be used as a treatment for relapsed or unresponsive chronic lymphocytic leukemia (CLL). This study concluded entospletinib has disease reducing activity in patients with CLL, where previous treatment has failed. Some background Chronic lymphocytic leukemia (CLL) is a cancer of the bone marrow. It...

Read More

Effectiveness of venetoclax in patients with unresponsive chronic lymphocytic leukemia

Posted by on Mar 9, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the effectiveness of venetoclax (Venclexta) in the treatment of relapsed or unresponsive chronic lymphocytic leukemia (CLL). Researchers found venetoclax improved outcomes in these patients. Some background CLL is a cancer of the bone marrow. This may lead to an abnormal immune system. It is also often...

Read More

Comparing ibrutinib and ofatumumab in patients with previously treated chronic lymphocytic leukemia

Posted by on Jan 28, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate patient well-being and patient-reported outcomes in previously treated patients with chronic lymphocytic leukemia who receive ibrutinib (Imbruvica) or ofatumumab (Arzerra). They concluded that ibrutinib can improve quality of life while prolonging survival in these patients. Some background...

Read More

Searching for patients with relapsed or unresponsive acute myeloid leukemia to test a new treatment

Posted by on Jan 2, 2019 in Leukemia | 0 comments

In a nutshell This trial is examining the effectiveness of a new drug called uproleselan for patients with acute myeloid leukemia (AML). The main outcome to be measured will be overall survival. This study is being conducted in the United States. The details Acute myeloid leukemia (AML) is a cancer of the bone marrow. It leads to an abnormal immune...

Read More

Evaluating the use of ibrutinib with bendamustine and rituximab treatment in unresponsive chronic lymphocytic leukemia

Posted by on Dec 8, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the safety and effectiveness of ibrutinib (Imbruvica) added to bendamustine (Treanda) and rituximab (Rituxan) in the treatment of unresponsive chronic lymphocytic leukemia. Researchers found that this treatment improved survival in these patients. Some background Chronic lymphocytic leukemia (CLL) is a...

Read More

Sequential treatment for patients with chronic lymphocytic leukemia who have received bendamustine

Posted by on Sep 17, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of obinutuzumab and venetoclax after bendamustine treatment in patients with chronic lymphocytic leukemia (CLL). This study concluded that this sequence of treatment caused no unexpected side effects. It also concluded that the outcomes were comparable to established therapies for CLL. Some...

Read More

Evaluating duvelisib for the treatment of CLL

Posted by on Aug 25, 2018 in Leukemia | 0 comments

In a nutshell This study evaluated the effectiveness and safety of duvelisib in patients with chronic lymphocytic leukemia (CLL). This study concluded that duvelisib may be an effective new therapy with manageable side effects. Some background CLL is the most common type of leukemia in adults in the U.S. Although therapy options have increased, many...

Read More

Evaluating nilotinib and dasatinib in pediatric patients with chronic myeloid leukemia

Posted by on Aug 21, 2018 in Leukemia | 0 comments

In a nutshell This study evaluated the effectiveness and safety of second-generation tyrosine kinase (TK) inhibitors after imatinib (Gleevec) therapy in children and adolescents with chronic myeloid leukemia (CML). The authors concluded that second-generation TK inhibitors may be a viable first-line treatment option for these patients. Some background...

Read More